Found: 16
Select item for more details and to access through your institution.
Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH).
- Published in:
- 2011
- By:
- Publication type:
- journal article
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County.
- Published in:
- Journal of Medical Virology, 2012, v. 84, n. 5, p. 777, doi. 10.1002/jmv.23267
- By:
- Publication type:
- Article
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma.
- Published in:
- Cancer Reports, 2023, v. 6, n. 5, p. 1, doi. 10.1002/cnr2.1803
- By:
- Publication type:
- Article
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 6, p. 722, doi. 10.1111/bjh.18593
- By:
- Publication type:
- Article
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 1, p. 60, doi. 10.1111/bjh.14992
- By:
- Publication type:
- Article
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e249, doi. 10.1016/j.clml.2019.09.413
- By:
- Publication type:
- Article
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e249, doi. 10.1016/j.clml.2019.09.412
- By:
- Publication type:
- Article
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
- Published in:
- British Journal of Cancer, 2022, v. 126, n. 3, p. 514, doi. 10.1038/s41416-021-01536-1
- By:
- Publication type:
- Article
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 5, p. 906, doi. 10.1002/hon.3066
- By:
- Publication type:
- Article
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 343, doi. 10.1007/s11523-024-01049-w
- By:
- Publication type:
- Article
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients.
- Published in:
- Targeted Oncology, 2023, v. 18, n. 5, p. 735, doi. 10.1007/s11523-023-00990-6
- By:
- Publication type:
- Article
Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia.
- Published in:
- Open Medicine, 2017, v. 12, n. 1, p. 76, doi. 10.1515/med-2017-0014
- By:
- Publication type:
- Article